Nykode Therapeutics AS (NYKD.OL)

NOK 2.59

(15.42%)

Long Term Debt Summary of Nykode Therapeutics AS

  • Nykode Therapeutics AS's latest annual long term debt in 2023 was 4.26 Million USD , down -2.2% from previous year.
  • Nykode Therapeutics AS's latest quarterly long term debt in 2024 Q2 was 3.38 Million USD , down 0.0% from previous quarter.
  • Nykode Therapeutics AS reported annual long term debt of 4.36 Million USD in 2022, down -25.0% from previous year.
  • Nykode Therapeutics AS reported annual long term debt of 5.82 Million USD in 2021, up 72650.0% from previous year.
  • Nykode Therapeutics AS reported quarterly long term debt of 3.74 Million USD for 2024 Q1, down 0.0% from previous quarter.
  • Nykode Therapeutics AS reported quarterly long term debt of 4.26 Million USD for 2023 FY, down -2.2% from previous quarter.

Annual Long Term Debt Chart of Nykode Therapeutics AS (2023 - 2016)

Historical Annual Long Term Debt of Nykode Therapeutics AS (2023 - 2016)

Year Long Term Debt Long Term Debt Growth
2023 4.26 Million USD -2.2%
2022 4.36 Million USD -25.0%
2021 5.82 Million USD 72650.0%
2020 8000.00 USD 0.0%
2019 - NOK 0.0%
2018 - NOK 0.0%
2017 - NOK 0.0%
2016 - NOK 0.0%

Peer Long Term Debt Comparison of Nykode Therapeutics AS

Name Long Term Debt Long Term Debt Difference
Arctic Bioscience AS 2.04 Million NOK -108.373%
Aqua Bio Technology ASA - NOK -Infinity%
ArcticZymes Technologies ASA 8.41 Million NOK 49.263%
BerGenBio ASA - NOK -Infinity%
Hofseth BioCare ASA 97.1 Million NOK 95.604%
PCI Biotech Holding ASA - NOK -Infinity%
Thor Medical ASA - NOK -Infinity%
Ultimovacs ASA 1.88 Million NOK -126.352%